Literature DB >> 28299611

Summarising the Evidence for Drug Safety: A Methodological Discussion of Different Meta-Analysis Approaches.

Guillermo Prada-Ramallal1, Bahi Takkouche1,2, Adolfo Figueiras3,4.   

Abstract

Evidence on drug safety obtained from randomised clinical trials is very limited due to, among other reasons, their relatively small sample size. Hence, combining the results of available studies can prove particularly useful. This paper reviews the different data sources for summarising drug safety outcomes, according to study design, publication of data, and origin of the information. It then discusses the various types of overviews that can be used in the study of treatment harms, focusing on meta-analyses of aggregate data and meta-analyses of individual patient data, with their advantages and drawbacks, such as publication bias and heterogeneity. Although the different approaches available for combining the results are of great utility in assessing treatment harms, none of them is free from limitations. Therefore, it might be appropriate to perform an analysis of sensitivity to assess whether the results are sensitive to the technique that has been used.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28299611     DOI: 10.1007/s40264-017-0518-1

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  76 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Relative citation impact of various study designs in the health sciences.

Authors:  Nikolaos A Patsopoulos; Apostolos A Analatos; John P A Ioannidis
Journal:  JAMA       Date:  2005-05-18       Impact factor: 56.272

3.  What is the best evidence for determining harms of medical treatment?

Authors:  Jan P Vandenbroucke
Journal:  CMAJ       Date:  2006-02-28       Impact factor: 8.262

4.  Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies.

Authors:  Panagiotis N Papanikolaou; Georgia D Christidi; John P A Ioannidis
Journal:  CMAJ       Date:  2006-02-28       Impact factor: 8.262

5.  Meta-analysis of continuous outcomes combining individual patient data and aggregate data.

Authors:  Richard D Riley; Paul C Lambert; Jan A Staessen; Jiguang Wang; Francois Gueyffier; Lutgarde Thijs; Florent Boutitie
Journal:  Stat Med       Date:  2008-05-20       Impact factor: 2.373

Review 6.  Utilization of health care databases for pharmacoepidemiology.

Authors:  Yasuo Takahashi; Yayoi Nishida; Satoshi Asai
Journal:  Eur J Clin Pharmacol       Date:  2011-08-02       Impact factor: 2.953

Review 7.  Meta-Analysis. Potentials and promise.

Authors:  M Egger; G D Smith
Journal:  BMJ       Date:  1997-11-22

Review 8.  Meta-analysis: statistical alchemy for the 21st century.

Authors:  A R Feinstein
Journal:  J Clin Epidemiol       Date:  1995-01       Impact factor: 6.437

9.  Assessment of publication bias, selection bias, and unavailable data in meta-analyses using individual participant data: a database survey.

Authors:  Ikhlaaq Ahmed; Alexander J Sutton; Richard D Riley
Journal:  BMJ       Date:  2012-01-03

Review 10.  Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews.

Authors:  Fujian Song; Yoon K Loke; Tanya Walsh; Anne-Marie Glenny; Alison J Eastwood; Douglas G Altman
Journal:  BMJ       Date:  2009-04-03
View more
  2 in total

1.  Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews.

Authors:  Emanuel Raschi; Matteo Bianchin; Milo Gatti; Alessandro Squizzato; Fabrizio De Ponti
Journal:  Drug Saf       Date:  2019-12       Impact factor: 5.606

2.  Primary versus secondary source of data in observational studies and heterogeneity in meta-analyses of drug effects: a survey of major medical journals.

Authors:  Guillermo Prada-Ramallal; Fatima Roque; Maria Teresa Herdeiro; Bahi Takkouche; Adolfo Figueiras
Journal:  BMC Med Res Methodol       Date:  2018-09-27       Impact factor: 4.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.